CN115298214A - 用于靶向淀粉样蛋白沉积物的经修饰的免疫球蛋白 - Google Patents
用于靶向淀粉样蛋白沉积物的经修饰的免疫球蛋白 Download PDFInfo
- Publication number
- CN115298214A CN115298214A CN202080092570.1A CN202080092570A CN115298214A CN 115298214 A CN115298214 A CN 115298214A CN 202080092570 A CN202080092570 A CN 202080092570A CN 115298214 A CN115298214 A CN 115298214A
- Authority
- CN
- China
- Prior art keywords
- amino acid
- acid sequence
- seq
- antibody
- cdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962936002P | 2019-11-15 | 2019-11-15 | |
| US62/936,002 | 2019-11-15 | ||
| US202063074912P | 2020-09-04 | 2020-09-04 | |
| US63/074,912 | 2020-09-04 | ||
| PCT/US2020/060596 WO2021097360A1 (en) | 2019-11-15 | 2020-11-13 | Modified immunoglobulins for targeting amyloid deposits |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115298214A true CN115298214A (zh) | 2022-11-04 |
Family
ID=75912899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080092570.1A Pending CN115298214A (zh) | 2019-11-15 | 2020-11-13 | 用于靶向淀粉样蛋白沉积物的经修饰的免疫球蛋白 |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US20220411489A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4058479A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7722990B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220113950A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115298214A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020385183A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022009273A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3158206A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL292903B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022005850A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021097360A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021097360A1 (en) | 2019-11-15 | 2021-05-20 | University Of Tennessee Research Foundation | Modified immunoglobulins for targeting amyloid deposits |
| US20240003912A1 (en) * | 2020-12-04 | 2024-01-04 | University Of Tennessee Research Foundation | Method for diagnosing amyloid diseases |
| US20240216556A1 (en) * | 2021-05-05 | 2024-07-04 | University Of Tennessee Research Foundation | Peptide-fc fusions for treating amyloid disorders |
| WO2022246433A1 (en) | 2021-05-18 | 2022-11-24 | University Of Tennessee Research Foundation | Antibody-peptide fusion proteins for treating amyloid disorders |
| WO2023043658A2 (en) * | 2021-09-14 | 2023-03-23 | Caelum Biosciences | Method of treating multiple myeloma |
| WO2023086989A1 (en) * | 2021-11-12 | 2023-05-19 | Adrx, Inc. | Transthyretin (ttr) monomer binding antibodies |
| WO2023220234A1 (en) * | 2022-05-11 | 2023-11-16 | Alexion Pharmaceuticals, Inc. | High sensitivity biotinylated peptide binding elisa assay |
| US20260070962A1 (en) * | 2022-09-02 | 2026-03-12 | University Of Tennessee Research Foundation | Chimeric antigen receptors for removal of amyloid |
| KR20260066110A (ko) | 2023-09-07 | 2026-05-12 | 유니버시티 오브 테네시 리서치 파운데이션 | 아밀로이드 질환을 진단하는 방법 |
| WO2025212955A1 (en) | 2024-04-05 | 2025-10-09 | University Of Tennessee Research Foundation | Method for diagnosing amyloid diseases |
| WO2026055521A1 (en) * | 2024-09-06 | 2026-03-12 | University Of Tennessee Research Foundation | Antibody-peptide fusion proteins for treating amyloid disorders |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008091954A2 (en) * | 2007-01-23 | 2008-07-31 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
| US20090202432A1 (en) * | 2007-12-28 | 2009-08-13 | Elan Pharmaceuticals, Inc. | Treatment and prophylaxis of amyloidosis |
| WO2016032949A1 (en) * | 2014-08-26 | 2016-03-03 | University Of Tennessee Research Foundation | Targeting immunotherapy for amyloidosis |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| JPH09506262A (ja) * | 1993-12-08 | 1997-06-24 | ジェンザイム・コーポレイション | 特異的抗体の製造方法 |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
| ES2345746T3 (es) * | 1998-05-21 | 2010-09-30 | University Of Tennessee Research Foundation | Metodos para la eliminacion de amiloide usando anticuerpos antiamiloide. |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
| KR101017732B1 (ko) * | 2002-03-01 | 2011-02-28 | 이뮤노메딕스, 인코오포레이티드 | 내재화 항-cd74 항체 및 그 이용방법 |
| CN101415724B (zh) | 2003-06-30 | 2015-12-02 | 特拉维夫大学未来科技开发有限公司 | 肽、抗肽抗体以及用它们来诊断和治疗淀粉样蛋白相关疾病的方法 |
| ATE439443T1 (de) | 2005-06-17 | 2009-08-15 | Ca Nat Research Council | NEUES Aß-BINDUNGSPROTEIN UND DESSEN PEPTIDDERIVATE SOWIE VERWENDUNGEN DAVON |
| US10076570B2 (en) | 2009-08-07 | 2018-09-18 | Transgene S.A. | Composition for treating HBV infection |
| WO2011119608A1 (en) | 2010-03-26 | 2011-09-29 | University Of Tennessee Research Foundation | Peptides that specifically target amyloid deposits |
| US20140079691A1 (en) | 2012-09-20 | 2014-03-20 | Anaptysbio, Inc. | Thermostable antibody framework regions |
| US9683017B2 (en) | 2014-07-17 | 2017-06-20 | University Tennessee Research Foundation | Inhibitory peptides of viral infection |
| JP7449092B2 (ja) | 2017-01-30 | 2024-03-13 | ナショナル リサーチ カウンシル オブ カナダ | 血液脳関門移動化合物及びその使用 |
| KR102607629B1 (ko) | 2017-06-29 | 2023-12-01 | 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 | 아밀로이드 침착 질환의 치료를 위한 키메라 항체 |
| US11382974B2 (en) | 2017-08-01 | 2022-07-12 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for treatment of amyloid deposition diseases |
| CN112513081A (zh) | 2018-06-14 | 2021-03-16 | 生物蛋白有限公司 | 多重特异性抗体构建体 |
| US12018069B2 (en) | 2018-06-28 | 2024-06-25 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for imaging amyloid deposits |
| WO2021097360A1 (en) | 2019-11-15 | 2021-05-20 | University Of Tennessee Research Foundation | Modified immunoglobulins for targeting amyloid deposits |
| WO2022246433A1 (en) | 2021-05-18 | 2022-11-24 | University Of Tennessee Research Foundation | Antibody-peptide fusion proteins for treating amyloid disorders |
-
2020
- 2020-11-13 WO PCT/US2020/060596 patent/WO2021097360A1/en not_active Ceased
- 2020-11-13 US US17/776,827 patent/US20220411489A1/en not_active Abandoned
- 2020-11-13 MX MX2022005850A patent/MX2022005850A/es unknown
- 2020-11-13 EP EP20887541.9A patent/EP4058479A4/en active Pending
- 2020-11-13 JP JP2022528305A patent/JP7722990B2/ja active Active
- 2020-11-13 KR KR1020227019864A patent/KR20220113950A/ko active Pending
- 2020-11-13 BR BR112022009273A patent/BR112022009273A2/pt unknown
- 2020-11-13 AU AU2020385183A patent/AU2020385183A1/en active Pending
- 2020-11-13 CA CA3158206A patent/CA3158206A1/en active Pending
- 2020-11-13 CN CN202080092570.1A patent/CN115298214A/zh active Pending
- 2020-11-13 IL IL292903A patent/IL292903B2/en unknown
-
2023
- 2023-03-09 US US18/181,489 patent/US12030934B2/en active Active
-
2024
- 2024-05-09 US US18/660,156 patent/US12157765B2/en active Active
- 2024-05-09 US US18/660,162 patent/US12264195B2/en active Active
-
2025
- 2025-02-12 US US19/052,001 patent/US20250368729A1/en active Pending
- 2025-06-20 JP JP2025104401A patent/JP7894099B2/ja active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008091954A2 (en) * | 2007-01-23 | 2008-07-31 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
| US20090202432A1 (en) * | 2007-12-28 | 2009-08-13 | Elan Pharmaceuticals, Inc. | Treatment and prophylaxis of amyloidosis |
| CN102016059A (zh) * | 2007-12-28 | 2011-04-13 | 依兰制药公司 | 淀粉样变性的治疗和预防 |
| WO2016032949A1 (en) * | 2014-08-26 | 2016-03-03 | University Of Tennessee Research Foundation | Targeting immunotherapy for amyloidosis |
Non-Patent Citations (3)
| Title |
|---|
| JAMES S FOSTER等: "A Peptide-Fc Opsonin with Pan-Amyloid Reactivity", 《FRONT IMMUNOL》, vol. 8, 4 September 2017 (2017-09-04), pages 1082 * |
| JAMES S. FOSTER等: "A Peptide-Fc Opsonin with Pan-Amyloid Reactivity", 《FRONT. IMMUNOL》, vol. 8, 4 September 2017 (2017-09-04), pages 1 - 14 * |
| PER WESTERMARK等: "Fibrils from designed non-amyloid-related synthetic peptides induce AA-amyloidosis during inflammation in an animal model", 《PLOS ONE》, vol. 4, no. 6, 30 June 2009 (2009-06-30), pages 6041 * |
Also Published As
| Publication number | Publication date |
|---|---|
| IL292903B2 (en) | 2026-04-01 |
| IL292903A (en) | 2022-07-01 |
| EP4058479A1 (en) | 2022-09-21 |
| US20220411489A1 (en) | 2022-12-29 |
| KR20220113950A (ko) | 2022-08-17 |
| WO2021097360A1 (en) | 2021-05-20 |
| AU2020385183A1 (en) | 2022-05-26 |
| EP4058479A4 (en) | 2024-02-28 |
| US20250368729A1 (en) | 2025-12-04 |
| JP2025134876A (ja) | 2025-09-17 |
| IL292903B1 (en) | 2025-12-01 |
| JP2023502968A (ja) | 2023-01-26 |
| MX2022005850A (es) | 2022-08-15 |
| JP7894099B2 (ja) | 2026-07-23 |
| US12157765B2 (en) | 2024-12-03 |
| CA3158206A1 (en) | 2021-05-20 |
| BR112022009273A2 (pt) | 2022-10-04 |
| US20240294621A1 (en) | 2024-09-05 |
| JP7722990B2 (ja) | 2025-08-13 |
| US20240294620A1 (en) | 2024-09-05 |
| US12264195B2 (en) | 2025-04-01 |
| US20230265178A1 (en) | 2023-08-24 |
| US12030934B2 (en) | 2024-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12030934B2 (en) | Modified immunoglobulins for targeting amyloid deposits | |
| US10646568B2 (en) | Targeting immunotherapy for amyloidosis | |
| EP3583123A1 (en) | Anti-tau antibodies and methods of use thereof | |
| JP2017031176A (ja) | 脳疾患を治療するための抗タウpS422抗体の使用 | |
| US20250101090A1 (en) | Antibody-peptide fusion proteins for treating amyloid disorders | |
| JP2022529344A (ja) | 治療及び診断のための新規分子 | |
| WO2019094608A1 (en) | Anti-bace1 antibodies and methods of use thereof | |
| US12630616B2 (en) | Complement C2 binding proteins and uses thereof | |
| WO2019094576A1 (en) | Bace-tau bispecific antibodies | |
| US10584175B2 (en) | FN14-binding proteins and uses thereof | |
| EA048681B1 (ru) | Модифицированные иммуноглобулины для нацеливания на амилоидные отложения | |
| EA051549B1 (ru) | Слитые белки антитело-пептид для лечения амилоидных дистрофий | |
| HK1166331B (en) | Use of an anti-tau ps422 antibody for the treatment of brain diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |